earnings
confidence high
sentiment positive
materiality 0.75
Adial reports Q3 net loss $1.8M, cash $4.6M; FDA provides Phase 3 guidance for AD04
ADIAL PHARMACEUTICALS, INC.
2025-Q3 EPS
reported -$0.45
vs consensus -$3.57
▲ beat
(+87.4%)
- Net loss $1.8M for Q3 2025 vs $2.2M in Q3 2024; R&D expenses down 50% YoY.
- Cash and equivalents $4.6M at Sep 30, 2025; runway into Q2 2026.
- Successful End of Phase 2 meeting with FDA; obtained guidance on Phase 3 design for AD04 (AUD).
- Analytical validation of cheek swab test with Genomind for biomarker-positive patients; FDA confirmed NSR, no IDE needed.
- Patent protection extended to at least 2045 via provisional patent update filed July 2025.